Brandl, E J
Tiwari, A K
Zai, C C
Nurmi, E L
Chowdhury, N I
Arenovich, T
Sanches, M
Goncalves, V F
Shen, J J
Lieberman, J A
Meltzer, H Y
Kennedy, J L
Müller, D J
Article History
Received: 17 May 2015
Accepted: 1 July 2015
First Online: 1 September 2015
Competing interests
: EJB/AKT/CCZ/VFG/NIC/DJM/JLK are authors on a patent application for a multigene model (not including SNPs presented here) predicting antipsychotic-induced weight gain. TA/MS/JJS/ELN: no competing interests. HYM has received grants or is or was a consultant to: Abbott Labs, ACADIA, Alkemes, Bristol Myers Squibb, DaiNippon Sumitomo, Eli Lilly, EnVivo, Janssen, Otsuka, Pfizer, Roche, Sunovion and BiolineRx. HYM is a shareholder of ACADIA and Glaxo Smith Kline. In the past 3 years JAL reports having received research funding or is a member of the advisory board of Allon, Alkermes Bioline, GlaxoSmithKline Intracellular Therapies, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Psychogenics, F Hoffmann-La Roche, Sepracor (Sunovion) and Targacept. JAL received no direct financial compensation or salary support for participation in these researches, consulting or advisory board activities. JLK has been a consultant to GSK, Sanofi-Aventis and Dainippon-Sumitomo.